KemPharm, Inc. (NASDAQ: KMPH) Starts Presentation at 29th Annual Roth Conference
KemPharm (NASDAQ: KMPH) is a clinical-stage specialty pharmaceutical company that discovers and develops new proprietary prodrugs in the United States. Its advanced product candidate is KP201/APAP, which consists of KP201 prodrug of hydrocodone formulated in combination with acetaminophen (APAP). The company is also developing KP201/APAP as an immediate release (IR) product candidate for the treatment of acute pain, as well as engages in designing KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse. The company is also involved in developing KP201/IR (APAP-free), an IR formulation of KP201 without APAP for the short-term management of acute pain. For more…







